 | Ground breaking molecular diagnostics business appoints new CEO現在、このページはご希望の言語でご利用いただけません。 Google 翻訳を使用すると自動翻訳でページを表示できます。 弊社はこのサービスの提供に責任を持たず、翻訳結果を弊社でチェックすることはありません。 David Burns appointed new CEO of D3 Technologies.
He will lead the Company towards the international launch of its first in-vitro diagnostic (IVD) products, with the aim to establish D3 Technologies as a global player in the field of molecular diagnostics for human infectious diseases. Mr Burns has over 20 years of commercial life sciences experience, most recently as VP of Sales & Marketing with Cyntellect Inc, and before that as Head of Strategic Growth with GE Healthcare Life Sciences. Professional, multi-disciplinary team
Mr Burns has gained extensive knowledge of sales, marketing and business development within the life sciences sector. Prior to GE Healthcare he also held senior roles within Amersham Biosciences, was CEO at Imaging Research Inc before its acquisition by Amersham, and VP of Business Development at BioSignal Packard Inc. “I am very excited by this new challenge,” said Mr Burns. “D3 Technologies has a tremendous future and I am looking forward to helping the team deliver world-class DNA-based diagnostic tests to detect diseases, or the genetic predisposition to diseases.” About D3 Technologies LtdD3 Technologies Ltd is a pioneer in trace level detection technologies based on the exploitation of Surface-Enhanced Raman Scattering (SERS) and Surface-Enhanced Resonance Raman Scattering (SERRS). By combining world-class nanometrology with unique Klarite® substrate technology, it serves a diverse range of fields including medical diagnostics, analytical applications, security and bio-defence, and forensic science. The Company is based in Glasgow, Scotland, and is part of the Renishaw Group, a world-leader in engineering, medical device and Raman spectroscopy technologies. Further information is available at www.d3diagnostics.com.
News updatesRegister for regular news updates from Renishaw Editor downloads
ImagesAll documents and images copyright Renishaw plc お問い合わせ詳細 や価格についてのお問い合わせは、オンラインでお寄せ下さい。直接コンタクトをご希望の場合は、 現地レニショーオフィスまでご連絡ください。 |
Glasgow, Scotland, 3rd February 2010: 
The Company’s current CEO, Professor Ewen Smith, is standing down to focus on the technical development of the exciting portfolio of diagnostics products that D3 Technologies has targeted for the next few years. Speaking about the new appointment he said, “I am delighted to welcome David to the Company. We already have a strong multi-disciplinary technical team and with his proven leadership skills, international experience of the clinical molecular diagnostics market and excellent track record in business development, the future is very bright for D3 Technologies.”
